The receipt of this permission paves way for the marketing of Durvalumab solution for infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India
Source:
www.thehindu.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.












